Hexuronate C4-epimerase variant having improved D-tagatose conversion activity, and D-tagatose production method using same

Patent metadata

Field	Value
Publication number	US-11306303-B2
Application number	US-201716083837-A
Country	US
Kind code	B2
Filing date	Jul 31, 2017
Priority date	Jul 29, 2016
Publication date	Apr 19, 2022
Grant date	Apr 19, 2022

Abstract

Provided are a hexuronate C4-epimerase variant with improved activity in converting D-fructose by D-tagatose of hexuronate C4-epimerase and a method for production of D-tagatose using them.

First claim

The invention claimed is:

1. A hexuronate C4-epimerase variant comprising an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 1, in which one or more amino acid residue selected from the group consisting of leucine (L) as an amino acid residue at position corresponding to 77, alanine (A) residue at position corresponding to 158, and proline (P) residue at position corresponding to 351, from the N-terminus of a hexuronate C4-epimerase of the amino acid sequence set forth in SEQ ID NO: 1 are mutated.

2. The hexuronate C4-epimerase variant according to claim 1 , wherein the leucine (L) residue at position corresponding to 77 is replaced by proline (P) or arginine (R).

3. The hexuronate C4-epimerase variant according to claim 1 , wherein the alanine (A) residue at position corresponding to 158 is replaced by threonine (T).

4. The hexuronate C4-epimerase variant according to claim 1 , wherein the proline (P) residue at position corresponding to 351 is replaced by serine (S).

5. The hexuronate C4-epimerase variant according to claim 1 , wherein in case the leucine (L) residue at position corresponding to 77 is replaced by proline (P) or arginine (R), one or more amino acid residue selected from the group consisting of serine (S) residue at position corresponding to 125, the alanine (A) residue at position corresponding to 158, the proline (P) residue at position corresponding to 351, from the N-terminus of the hexuronate C4-epimerase of the amino acid sequence set forth in SEQ ID NO: 1 are further mutated.

6. The hexuronate C4-epimerase variant according to claim 1 , wherein in case the alanine (A) residue at position corresponding to 158 is replaced by threonine (T), one or more amino acid residue selected from the group consisting of serine (S) residue at position corresponding to 125, the glutamine (Q) residue at position corresponding to 149, the valine (V) residue at position corresponding to 267, and the proline (P) residue at position corresponding to 351, from the N-terminus of the hexuronate C4-epimerase of SEQ ID NO: 1 are further mutated.

7. The hexuronate C4-epimerase variant according to claim 1 , wherein in case the proline (P) residue at position corresponding to 351 is replaced by serine (S), one or more amino acid residue selected from the group consisting of serine (S) residue at position corresponding to 125, and the valine (V) residue at position corresponding to 267, from the N-terminus of the hexuronate C4-epimerase are further mutated.

8. The hexuronate C4-epimerase variant according to claim 1 , wherein serine (S) residue at position corresponding to 125 from the N-terminus of a hexuronate C4-epimerase of the amino acid sequence set forth in SEQ ID NO: 1 is further mutated.

9. The hexuronate C4-epimerase variant according to claim 8 , wherein the serine (S) residue at position corresponding to 125 is replaced by aspartic acid (D), glutamine (Q), glutamic acid (E), threonine (T), asparagine (N), cysteine (C), or tyrosine (Y).

10. The hexuronate C4-epimerase variant according to claim 8 , in which serine (S) as an amino acid residue at position corresponding to 125, lysine (K) as an amino acid residue at position corresponding to 164, aspartic acid (D) as an amino acid residue at position corresponding to 168, and glutamic acid (E) as an amino acid residue at position corresponding to 175 from the N-terminus of a hexuronate C4-epimerase of the amino acid sequence set forth in SEQ ID NO: 1 are mutated.

11. The hexuronate C4-epimerase variant according to claim 8 , in which serine (S) as an amino acid residue at position corresponding to 125, glutamine (Q) as an amino acid residue at position corresponding to 149, and valine (V) as an amino acid residue at position corresponding to 267 from the N-terminus of a hexuronate C4-epimerase of the amino acid sequence set forth in SEQ ID NO:
1 are mutated.

12. The hexuronate C4-epimerase variant according to claim 1 , wherein one or more amino acid residue selected from the group consisting of glutamine (Q) residue at position corresponding to 149, lysine (K) residue at position corresponding to 164, aspartic acid (D) residue at position corresponding to 168, glutamic acid (E) residue at position corresponding to 175, and valine (V) residue at position corresponding to 267, from the N-terminus of the hexuronate C4-epimerase of the amino acid sequence set forth in SEQ ID NO: 1 are further mutated.

13. A nucleic acid encoding the hexuronate C4-epimerase variant according to claim 12 .

14. A method for D-tagatose production comprising bringing the hexuronate C4-epimerase variant according to claim 12 , a microorganism or a culture thereof expressing the variant into contact with D-fructose.

15. A nucleic acid encoding the hexuronate C4-epimerase variant according to claim 1 .

16. A method for D-tagatose production comprising bringing the hexuronate C4-epimerase variant according to claim 1 , a microorganism or a culture thereof expressing the variant into contact with D-fructose.

17. The hexuronate C4-epimerase variant according to claim 1 , wherein the hexuronate C4-epimerase variant comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1.

18. The hexuronate C4-epimerase variant according to claim 1 , wherein the hexuronate C4-epimerase variant comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1.

19. The hexuronate C4-epimerase variant according to claim 1 , wherein the hexuronate C4-epimerase variant comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1.

20. The hexuronate C4-epimerase variant according to claim 1 , wherein the hexuronate C4-epimerase variant comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1.

Assignees

• Cj Cheiljedang Corp

Inventors

• Yang Sung Jae
• Lee Young Mi
• Park Il Hyang
• Lee Chan-Hyoung
• Cho Hyun Kug
• Kim Seong Bo
• Kim Yang Hee
• Park Seung Won

Classifications

• C12N9/90 Primary

  Isomerases (5.) · CPC title

• C12P19/02

  Monosaccharides (2-ketogulonic acid C12P7/60) · CPC title

• C12Y501/03

  acting on carbohydrates and derivatives (5.1.3) · CPC title

• C12P19/24

  produced by the action of an isomerase, e.g. fructose · CPC title

• C12Y501/02

  acting on hydroxy acids and derivatives (5.1.2) · CPC title